drugset / Trial / NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2
Completed
50 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabGenzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce. When these enzymes are blocked, the cancer call can no longer prepare the DNA needed to make new cells. Clofarabine also encourages existing cancer cells to die by disturbing components within the cancer cell. This causes the release of a substance that is fatal to the cell. This trial studies the efficacy of oral clofarabine in the treatment of relapsed non-Hodgkin lymphomas.
Timeline
- Start
- 2008-06
- Primary completion
- 2013-12
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | — | Oral |